Yasser Fouad,Abdulla Al Hassani,Nawal Alkhalidi et al.
Yasser Fouad et al.
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer [0.03%]
胆道癌辅助治疗中识别信号困难性
Julien Edeline,John Bridgewater
Julien Edeline
Mohammed Nabil Quraishi,Badr Al-Bawardy
Mohammed Nabil Quraishi
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial [0.03%]
回结肠切除术与英夫利昔治疗克罗恩病的长期结局：LIR!C试验的回顾性10年随访研究
Lotte Oldenburg,Anouck E G Haanappel,Mahsoem Ali et al.
Lotte Oldenburg et al.
Background: The LIR!C trial showed that laparoscopic ileocaecal resection is an effective alternative to infliximab therapy with similar quality-of-life outcomes in patients with uncomplicated ileocaecal Crohn's disease w...
Delivering therapeutic diets for gastrointestinal disease to people with intellectual disabilities [0.03%]
向智障人士提供胃肠疾病治疗饮食护理
Lynette Harper,Ian H Walshe,Leigh Donnelly
Lynette Harper
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study [0.03%]
VS-01腹腔给药脂质体输液在失代偿期肝硬化、腹水和隐匿性肝性脑病患者中的安全性、药动学及初步有效性：一项Ib期首次人体、开放标签、非随机、单次及多次递增剂量研究
Frank Erhard Uschner,Martin McCoy,Olaf Tyc et al.
Frank Erhard Uschner et al.
Background: Acute-on-chronic liver failure (ACLF) is characterised by systemic inflammation and organ failures in patients with decompensated liver cirrhosis. In the absence of specific approved treatments, ACLF is associ...
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response [0.03%]
来自一线的声音：全球资金削减如何重塑病毒性肝炎应对措施
Marion Delphin,Monica Fambrough,Jana Manning et al.
Marion Delphin et al.
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management [0.03%]
代谢功能紊乱相关steatohepatitis的药物治疗：心肝共管
Xiao-Dong Zhou,Jeffrey V Lazarus,Chayakrit Krittanawong et al.
Xiao-Dong Zhou et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults, with about 30% of cases progressing to metabolic dysfunction-associated steatohepatitis (MASH), which can lead to cirrhosis and hepatocell...